Key Takeaways FOLD shares surged 135.8% in six months, far outpacing the industry, sector and the S&P 500 index.Amicus is set to be acquired by BioMarin in a $4.8B deal expected to be closed in the second quarter of 2026.Galafold and Pombiliti Opfolda posted steady sales growth in 2025, driving revenue momentum.Shares of Amicus Therapeutics (FOLD) have witnessed a strong surge in the past six months, primarily driven by the growing momentum of its marketed products and the recently announced merger agreemen ...